These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 31082851)

  • 21. Serum biomarkers evaluation to predict chemotherapy-induced cardiotoxicity in breast cancer patients.
    De Iuliis F; Salerno G; Taglieri L; De Biase L; Lanza R; Cardelli P; Scarpa S
    Tumour Biol; 2016 Mar; 37(3):3379-87. PubMed ID: 26449821
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiotoxicity and Cardiac Monitoring During Adjuvant Trastuzumab in Daily Dutch Practice: A Study of the Southeast Netherlands Breast Cancer Consortium.
    Seferina SC; de Boer M; Derksen MW; van den Berkmortel F; van Kampen RJ; van de Wouw AJ; Joore M; Peer PG; Voogd AC; Tjan-Heijnen VC
    Oncologist; 2016 May; 21(5):555-62. PubMed ID: 27009939
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modern Management of Anthracycline-Induced Cardiotoxicity in Lymphoma Patients: Low Occurrence of Cardiotoxicity with Comprehensive Assessment and Tailored Substitution by Nonpegylated Liposomal Doxorubicin.
    Olivieri J; Perna GP; Bocci C; Montevecchi C; Olivieri A; Leoni P; Gini G
    Oncologist; 2017 Apr; 22(4):422-431. PubMed ID: 28275118
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anthracycline-related cardiotoxicity in childhood cancer survivors.
    Lipshultz SE; Karnik R; Sambatakos P; Franco VI; Ross SW; Miller TL
    Curr Opin Cardiol; 2014 Jan; 29(1):103-12. PubMed ID: 24284979
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HER2-targeted liposomal doxorubicin displays enhanced anti-tumorigenic effects without associated cardiotoxicity.
    Reynolds JG; Geretti E; Hendriks BS; Lee H; Leonard SC; Klinz SG; Noble CO; Lücker PB; Zandstra PW; Drummond DC; Olivier KJ; Nielsen UB; Niyikiza C; Agresta SV; Wickham TJ
    Toxicol Appl Pharmacol; 2012 Jul; 262(1):1-10. PubMed ID: 22676972
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rationale and design of a cardiac safety study for reduced cardiotoxicity surveillance during HER2-targeted therapy.
    Yu AF; Dang CT; Jorgensen J; Moskowitz CS; DeFusco P; Oligino E; Oeffinger KC; Liu JE; Steingart RM
    Cardiooncology; 2023 Mar; 9(1):13. PubMed ID: 36895062
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anthracycline-trastuzumab regimens for HER2/neu-overexpressing breast cancer: current experience and future strategies.
    Rayson D; Richel D; Chia S; Jackisch C; van der Vegt S; Suter T
    Ann Oncol; 2008 Sep; 19(9):1530-9. PubMed ID: 18480068
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of anthracyclines in the treatment of early breast cancer.
    Greene J; Hennessy B
    J Oncol Pharm Pract; 2015 Jun; 21(3):201-12. PubMed ID: 24769570
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardiac Safety of Dual Anti-HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2-Positive Breast Cancer.
    Yu AF; Singh JC; Wang R; Liu JE; Eaton A; Oeffinger KC; Steingart RM; Hudis CA; Dang CT
    Oncologist; 2017 Jun; 22(6):642-647. PubMed ID: 28341761
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Troponin I and B-type Natriuretic Peptide (BNP) as biomarkers for the prediction of cardiotoxicity in patients with breast cancer treated with adjuvant anthracyclines and trastuzumab].
    Pistillucci G; Ciorra AA; Sciacca V; Raponi M; Rossi R; Veltri E
    Clin Ter; 2015; 166(1):e67-71. PubMed ID: 25756270
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101-Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity.
    Pituskin E; Mackey JR; Koshman S; Jassal D; Pitz M; Haykowsky MJ; Pagano JJ; Chow K; Thompson RB; Vos LJ; Ghosh S; Oudit GY; Ezekowitz JA; Paterson DI
    J Clin Oncol; 2017 Mar; 35(8):870-877. PubMed ID: 27893331
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Two-dimensional speckle tracking echocardiography predicts early subclinical cardiotoxicity associated with anthracycline-trastuzumab chemotherapy in patients with breast cancer.
    Arciniegas Calle MC; Sandhu NP; Xia H; Cha SS; Pellikka PA; Ye Z; Herrmann J; Villarraga HR
    BMC Cancer; 2018 Oct; 18(1):1037. PubMed ID: 30359235
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Human epidermal growth factor antagonists and cardiotoxicity-A short review of the problem and preventative measures.
    Dias A; Claudino W; Sinha R; Perez CA; Jain D
    Crit Rev Oncol Hematol; 2016 Aug; 104():42-51. PubMed ID: 27338847
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anthracycline-induced cardiotoxicity in children with cancer: strategies for prevention and management.
    Iarussi D; Indolfi P; Casale F; Martino V; Di Tullio MT; Calabrò R
    Paediatr Drugs; 2005; 7(2):67-76. PubMed ID: 15871628
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Incidence and identification of risk factors for trastuzumab-induced cardiotoxicity in breast cancer patients: an audit of a single "real-world" setting.
    Tang GH; Acuna SA; Sevick L; Yan AT; Brezden-Masley C
    Med Oncol; 2017 Sep; 34(9):154. PubMed ID: 28779423
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cardiotoxicity of ErbB2-targeted therapies and its impact on drug development, a spotlight on trastuzumab.
    Dokmanovic M; King KE; Mohan N; Endo Y; Wu WJ
    Expert Opin Drug Metab Toxicol; 2017 Jul; 13(7):755-766. PubMed ID: 28571477
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Global Longitudinal Strain Accuracy for Cardiotoxicity Prediction in a Cohort of Breast Cancer Patients During Anthracycline and/or Trastuzumab Treatment.
    Gripp EA; Oliveira GE; Feijó LA; Garcia MI; Xavier SS; Sousa AS
    Arq Bras Cardiol; 2018 Feb; 110(2):140-150. PubMed ID: 29561992
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adjuvant therapy for HER2 positive breast cancer: are anthracyclines still necessary?
    Castrellon AB; Glück S
    Clin Adv Hematol Oncol; 2008 Sep; 6(9):666-72. PubMed ID: 18827789
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anthracycline-Induced Cardiomyopathy in Adults.
    Tan TC; Neilan TG; Francis S; Plana JC; Scherrer-Crosbie M
    Compr Physiol; 2015 Jul; 5(3):1517-40. PubMed ID: 26140726
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase 2 randomized trial to evaluate the impact of a supervised exercise program on cardiotoxicity at 3 months in patients with HER2 overexpressing breast cancer undergoing adjuvant treatment by trastuzumab: design of the CARDAPAC study.
    Jacquinot Q; Meneveau N; Chatot M; Bonnetain F; Degano B; Bouhaddi M; Dumoulin G; Vernerey D; Pivot X; Mougin F
    BMC Cancer; 2017 Jun; 17(1):425. PubMed ID: 28629338
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.